Stiolto Respimat received approval from the Food and Drug Administration (FDA) in May 2015. The Respimat inhaler actively delivers a slow-moving mist that aids the patient independent of inspiratory ...
In addition to the new exacerbation data, the indication for Stiolto Respimat has been revised. The Food and Drug Administration (FDA) has approved updated labeling for Stiolto Respimat (tiotropium ...
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO™ RESPIMAT ® (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the ...
A few months after the FDA cleared digital health company Propeller Health’ first collaboration with Boehringer Ingelheim to use its remote monitoring platform with BI’s Respimat inhaler, the FDA has ...
The US Food and Drug Administration (FDA) last week approved a once-daily oral inhalation spray combining tiotropium and olodaterol (Stiolto Respimat, Boehringer Ingelheim) for chronic obstructive ...
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat ® (tiotropium bromide and olodaterol) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback